
(1) Non-GAAP adjusted net loss, non-GAAP adjusted net loss attributable to common stockholders, and non-GAAP adjusted net loss per diluted common share are non-GAAP measures. See page 5 for reconciliations of these non-GAAP financial measures to the most comparable GAAP financial measures. | ||
June 30, 2026 | December 31, 2025 | ||
(unaudited) | (audited) | ||
Assets: | |||
Current assets: | |||
Cash and cash equivalents | $145,466 | $67,499 | |
Investments in preferred equity, at fair value | 42,854 | — | |
Prepaid expenses | 2,018 | 2,708 | |
Other current assets | 2,231 | 1,569 | |
Total current assets | 192,569 | 71,776 | |
Digital assets, at fair value | 1,164,639 | 668,486 | |
Property and equipment, net | 798 | 778 | |
Intangible assets, net | 14,982 | 355 | |
Right-of-use lease assets | 3,825 | 4,037 | |
Other non-current assets | 296 | 95 | |
Total assets | $1,377,109 | $745,527 | |
Liabilities: | |||
Current liabilities: | |||
Compensation and benefits payable | $9,624 | $164 | |
Accounts payable and other liabilities | 7,146 | 8,560 | |
Dividends payable | 8,492 | 2,053 | |
Total current liabilities | 25,262 | 10,777 | |
Operating lease liabilities | 3,319 | 3,512 | |
Total liabilities | 28,581 | 14,289 | |
Mezzanine equity: | |||
Variable Rate Series A Preferred Stock, $0.001 par value; 40,000,000 and 20,000,000 shares authorized, 7,829,502 and 2,012,729 shares issued and outstanding, $783.0 million and $201.3 million redemption value and liquidation preference as of June 30, 2026 and December 31, 2025, respectively | 702,373 | 148,802 | |
Total mezzanine equity | 702,373 | 148,802 | |
Stockholders’ equity: | |||
Class A common stock, $0.001 par value; 22,200,000,000 shares authorized, 72,164,809 and 34,936,745 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 72 | 699 | |
Class B common stock, $0.001 par value; 1,050,000,000 shares authorized, 9,780,018 and 9,776,540 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 10 | 196 | |
Additional paid-in capital | 1,683,299 | 1,055,595 | |
Accumulated deficit | (1,037,226) | (474,054) | |
Total stockholders’ equity | 646,155 | 582,436 | |
Total liabilities, mezzanine equity, and stockholders' equity | $1,377,109 | $745,527 |
Successor | Predecessor | |||
Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | |||
Revenues: | ||||
Investment advisory fees | $1,512 | $1,488 | ||
Medical device revenues | 1,388 | — | ||
Other revenue | 41 | 23 | ||
Total revenues | 2,941 | 1,511 | ||
Operating expenses: | ||||
Fund management and administration | 1,489 | 1,588 | ||
Employee compensation and benefits | 16,314 | 2,005 | ||
General and administrative expense | 6,428 | 1,452 | ||
Marketing and advertising | 79 | 102 | ||
Depreciation and amortization | 86 | 54 | ||
Total operating expenses | 24,396 | 5,201 | ||
Investment losses: | ||||
Net unrealized loss on digital assets, at fair value | (228,031) | — | ||
Net unrealized loss on investments in preferred equity, at fair value | (5,962) | — | ||
Other investment loss | (2,801) | — | ||
Total investment losses | (236,794) | — | ||
Net operating loss | (258,249) | (3,690) | ||
Other income/(expense): | ||||
Other income | 955 | 252 | ||
Interest expense on long-term notes payable, at fair value | (40) | — | ||
Change in fair value on long-term notes payable, at fair value | (299) | — | ||
Gain on extinguishment of debt | 30 | — | ||
Transaction costs | — | (5,437) | ||
Total other income/(expense) | 646 | (5,185) | ||
Net loss before income taxes | (257,603) | (8,875) | ||
Income tax benefit/(expense) | — | — | ||
Net loss | $(257,603) | $(8,875) | ||
Dividends on preferred stock | (26,209) | — | ||
Net loss attributable to common stockholders | $(283,812) | $(8,875) | ||
Weighted average number of common shares outstanding: | ||||
Basic (1) | 75,275,806 | 2,300,998 | ||
Diluted (1) | 75,275,806 | 2,300,998 | ||
Net loss per common share: | ||||
Basic (1) | $(3.77) | $(3.86) | ||
Diluted (1) | $(3.77) | $(3.86) |
Successor | Predecessor | |||
Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 | |||
Revenues: | ||||
Investment advisory fees | $2,859 | $2,904 | ||
Medical device revenues | 2,758 | — | ||
Other revenue | 84 | 30 | ||
Total revenues | 5,701 | 2,934 | ||
Operating expenses: | ||||
Fund management and administration | 2,913 | 2,999 | ||
Employee compensation and benefits | 29,367 | 4,071 | ||
General and administrative expense | 12,366 | 3,358 | ||
Marketing and advertising | 195 | 163 | ||
Depreciation and amortization | 176 | 106 | ||
Total operating expenses | 45,017 | 10,697 | ||
Investment losses: | ||||
Net unrealized loss on digital assets, at fair value | (523,809) | — | ||
Net unrealized loss on investments in preferred equity, at fair value | (5,472) | — | ||
Other investment loss | (2,801) | — | ||
Total investment losses | (532,082) | — | ||
Net operating loss | (571,398) | (7,763) | ||
Other income/(expense): | ||||
Other income | 1,481 | 576 | ||
Interest expense on long-term notes payable, at fair value | (282) | — | ||
Change in fair value on long-term notes payable, at fair value | (2,464) | — | ||
Loss on extinguishment of debt | (8,431) | — | ||
Loss on change in fair value of bitcoin held as collateral under Coinbase Loan | (2,594) | — | ||
Transaction costs | (6,525) | (5,437) | ||
Bargain purchase gain | 66,704 | — | ||
Total other income/(expense) | 47,889 | (4,861) | ||
Net loss before income taxes | (523,509) | (12,624) | ||
Income tax benefit/(expense) | — | — | ||
Net loss | $(523,509) | $(12,624) | ||
Dividends on preferred stock | (39,663) | — | ||
Net loss attributable to common stockholders | $(563,172) | $(12,624) | ||
Weighted average number of common shares outstanding: | ||||
Basic (1) | 68,490,600 | 2,288,538 | ||
Diluted (1) | 68,490,600 | 2,288,538 | ||
Net loss per common share: | ||||
Basic (1) | (8.22) | (5.52) | ||
Diluted (1) | (8.22) | (5.52) |
Three Months Ended | Six Months Ended | ||||||||
June 30, 2026 | June 30, 2025 | June 30, 2026 | June 30, 2025 | ||||||
Successor | Predecessor | Successor | Predecessor | ||||||
Net loss | $(257,603) | $(8,875) | $(523,509) | $(12,624) | |||||
Share-based compensation expense | 5,684 | — | 12,213 | — | |||||
Depreciation and amortization | 86 | 54 | 176 | 106 | |||||
Other investment loss | 2,801 | — | 2,801 | — | |||||
Change in fair value on long-term notes payable, at fair value | 299 | — | 2,464 | — | |||||
(Gain)/loss on extinguishment of debt | (30) | — | 8,431 | — | |||||
Loss on change in fair value of bitcoin held as collateral under Coinbase Loan | — | — | 2,594 | — | |||||
Transaction costs | — | 5,437 | 6,525 | 5,437 | |||||
Bargain purchase gain | — | — | (66,704) | — | |||||
Non-GAAP adjusted net income (loss) | $(248,763) | $(3,384) | $(555,009) | $(7,081) | |||||
Dividends on preferred stock | (26,209) | — | (39,663) | — | |||||
Non-GAAP adjusted net loss attributable to common stockholders | $(274,972) | $(3,384) | $(594,672) | $(7,081) | |||||
Weighted average number of diluted common shares outstanding | 75,275,806 | 2,300,998 | 68,490,600 | 2,288,538 | |||||
Net loss per diluted common share | $(3.77) | $(3.86) | $(8.22) | $(5.52) | |||||
Non-GAAP adjusted net loss per diluted common share | $(3.65) | $(1.47) | $(8.68) | $(3.09) | |||||